|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression |
ISO |
annomontine results in increased expression of AHR mRNA |
CTD |
PMID:20449727 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Ahrr |
aryl-hydrocarbon receptor repressor |
increases expression |
ISO |
annomontine results in increased expression of AHRR mRNA |
CTD |
PMID:20449727 |
|
NCBI chr 1:31,603,297...31,698,329
Ensembl chr 1:31,603,297...31,698,329
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
annomontine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:20449727 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases activity |
ISO |
norharman inhibits the reaction [Lipids metabolite results in increased activity of AHR protein] norharman results in increased activity of AHR protein |
CTD |
PMID:27020609 PMID:28336214 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
CYP1A1 protein affects the metabolism of [norharman co-treated with aniline] norharman results in increased expression of CYP1A1 mRNA; norharman results in increased expression of CYP1A1 protein |
CTD |
PMID:15279827 PMID:28336214 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
CYP1A2 protein affects the metabolism of [norharman co-treated with aniline] |
CTD |
PMID:15279827 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
CYP1B1 protein affects the metabolism of [norharman co-treated with aniline] |
CTD |
PMID:15279827 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
CYP2B6 protein affects the metabolism of [norharman co-treated with aniline] |
CTD |
PMID:15279827 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
ISO |
CYP2D6 protein affects the metabolism of [norharman co-treated with aniline] |
CTD |
PMID:15279827 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
CYP2E1 protein affects the metabolism of [norharman co-treated with aniline] |
CTD |
PMID:15279827 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
CYP3A4 protein affects the metabolism of [norharman co-treated with aniline] |
CTD |
PMID:15279827 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
norharman results in decreased activity of MAOA protein |
CTD |
PMID:28057462 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
G |
Maob |
monoamine oxidase B |
multiple interactions decreases activity |
ISO |
norharman inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] norharman results in decreased activity of MAOB protein |
CTD |
PMID:21554916 |
|
NCBI chr X:6,430,694...6,533,520
Ensembl chr X:6,430,594...6,533,534
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
decreases activity multiple interactions |
ISO |
norharman results in decreased activity of SLC22A1 protein norharman inhibits the reaction [SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] |
CTD |
PMID:30189235 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
decreases activity multiple interactions |
ISO |
norharman results in decreased activity of SLC22A2 protein norharman inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] |
CTD |
PMID:30189235 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
decreases activity multiple interactions |
ISO |
norharman results in decreased activity of SLC22A3 protein norharman inhibits the reaction [SLC22A3 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] |
CTD |
PMID:30189235 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of ABCB1 protein] |
CTD |
PMID:15710601 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased activity of AKT1 protein]; wortmannin promotes the reaction [evodiamine results in decreased phosphorylation of AKT1 protein] evodiamine inhibits the reaction [INS1 results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:15710601 PMID:17884939 PMID:20005289 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases cleavage |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [evodiamine results in increased cleavage of BCL2 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BCL2 protein] |
CTD |
PMID:15710601 PMID:20005289 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein] |
CTD |
PMID:15710601 |
|
NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein] |
CTD |
PMID:15710601 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] |
CTD |
PMID:15710601 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of BIRC3 protein] |
CTD |
PMID:15710601 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of BIRC5 protein] |
CTD |
PMID:15710601 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [evodiamine results in increased activity of and results in increased cleavage of CASP3 protein]; evodiamine results in increased activity of and results in increased cleavage of CASP3 protein |
CTD |
PMID:20005289 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of CCND1 protein] |
CTD |
PMID:15710601 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of CFLAR protein] |
CTD |
PMID:15710601 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased activity of CHUK protein] |
CTD |
PMID:15710601 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of PLCG1 protein]; EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of PRKCA protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of EGFR protein] |
CTD |
PMID:19854188 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [evodiamine results in increased expression of FASLG protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [evodiamine results in increased expression of FASLG protein]; wortmannin inhibits the reaction [evodiamine results in increased expression of FASLG protein] |
CTD |
PMID:20005289 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:15710601 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased activity of IKBKB protein] |
CTD |
PMID:15710601 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
evodiamine inhibits the reaction [IL1B protein results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [IL1B protein results in increased activity of RELA protein] |
CTD |
PMID:15710601 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
chelerythrine inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:17884939 PMID:19854188 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
chelerythrine inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17884939 PMID:19854188 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [evodiamine results in increased expression of MAPK8 protein modified form] |
CTD |
PMID:23774672 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [evodiamine results in increased expression of MAPK9 protein modified form] |
CTD |
PMID:23774672 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of MMP9 protein] |
CTD |
PMID:15710601 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of MYC protein] |
CTD |
PMID:15710601 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
evodiamine inhibits the reaction [Hydrogen Peroxide results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [IL1B protein results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; evodiamine inhibits the reaction [TNF protein results in increased activity of NFKB1 protein] |
CTD |
PMID:15710601 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [evodiamine results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; evodiamine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; evodiamine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; evodiamine results in increased phosphorylation of and results in increased degradation of NFKBIA protein; wortmannin inhibits the reaction [evodiamine results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:15710601 PMID:20005289 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
evodiamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:17109845 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
evodiamine promotes the reaction [TNF protein results in increased cleavage of PARP1 protein] |
CTD |
PMID:15710601 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions increases phosphorylation |
ISO |
EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of PLCG1 protein] |
CTD |
PMID:19854188 |
|
NCBI chr 3:156,727,642...156,758,307
Ensembl chr 3:156,727,642...156,758,307
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
evodiamine results in decreased expression of PPARG |
CTD |
PMID:17884939 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions increases phosphorylation |
ISO |
EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of PRKCA protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of PRKCA protein] |
CTD |
PMID:19854188 |
|
NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of PTGS2 protein] |
CTD |
PMID:15710601 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
evodiamine inhibits the reaction [Hydrogen Peroxide results in increased activity of RELA protein]; evodiamine inhibits the reaction [IL1B protein results in increased activity of RELA protein]; evodiamine inhibits the reaction [Okadaic Acid results in increased activity of RELA protein]; evodiamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of RELA protein]; evodiamine inhibits the reaction [TNF protein affects the localization of RELA protein]; evodiamine inhibits the reaction [TNF protein results in increased acetylation of RELA protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; evodiamine inhibits the reaction [TNF protein results in increased activity of RELA protein] |
CTD |
PMID:15710601 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein affects the localization of RELA protein]; evodiamine inhibits the reaction [TNF protein results in increased acetylation of RELA protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; evodiamine inhibits the reaction [TNF protein results in increased activity of AKT1 protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of CHUK protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of IKBKB protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of RELA protein]; evodiamine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of ABCB1 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of MYC protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of XIAP protein]; evodiamine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; evodiamine promotes the reaction [TNF protein results in increased cleavage of PARP1 protein] |
CTD |
PMID:15710601 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
evodiamine inhibits the reaction [TNF protein results in increased expression of XIAP protein] |
CTD |
PMID:15710601 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Harmaline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 protein] |
CTD |
PMID:12107048 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity decreases stability |
ISO |
[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein]; Harmaline inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; Harmaline inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of CYP1A1 protein]; Harmaline inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] Harmaline results in decreased activity of CYP1A1 protein Harmaline results in decreased stability of CYP1A1 protein |
CTD |
PMID:22037238 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Harmaline inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Harmaline inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:12065299 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
EXP ISO |
Harmaline results in decreased activity of MAOA protein |
CTD |
PMID:15178694 PMID:24373881 PMID:28302559 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Harmaline inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Harmaline inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of NFKB1 protein] |
CTD |
PMID:12065299 PMID:12107048 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Harmaline inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Harmaline inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of RELA protein] |
CTD |
PMID:12065299 PMID:12107048 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression |
ISO |
harmalol results in increased activity of CASP3 protein harmalol results in increased expression of CASP3 mRNA |
CTD |
PMID:27590872 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases stability decreases activity |
ISO |
[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein]; harmalol inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; harmalol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of CYP1A1 protein]; harmalol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] harmalol results in decreased stability of CYP1A1 protein harmalol results in decreased activity of CYP1A1 protein |
CTD |
PMID:22037238 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
harmalol results in increased expression of TP53 mRNA; harmalol results in increased expression of TP53 protein |
CTD |
PMID:27590872 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
AHR mutant form inhibits the reaction [harman results in increased activity of CYP1A1 protein]; AHR mutant form inhibits the reaction [harman results in increased expression of CYP1A1 protein] |
CTD |
PMID:20732341 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases activity increases expression |
ISO EXP |
AHR mutant form inhibits the reaction [harman results in increased activity of CYP1A1 protein]; AHR mutant form inhibits the reaction [harman results in increased expression of CYP1A1 protein]; Dactinomycin inhibits the reaction [harman results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [harman results in increased activity of CYP1A1 protein] harman results in increased expression of CYP1A1 mRNA; harman results in increased expression of CYP1A1 protein |
CTD |
PMID:20732341 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
harman results in decreased activity of MAOA protein |
CTD |
PMID:28057462 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions decreases activity |
ISO |
harman inhibits the reaction [SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] harman results in decreased activity of SLC22A1 protein |
CTD |
PMID:30189235 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
decreases activity multiple interactions |
ISO |
harman results in decreased activity of SLC22A2 protein harman inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] |
CTD |
PMID:30189235 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Taar1 |
trace-amine-associated receptor 1 |
increases activity multiple interactions |
ISO |
harman results in increased activity of TAAR1 protein [harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:19725810 |
|
NCBI chr 1:22,595,477...22,596,475
Ensembl chr 1:22,595,477...22,596,475
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Harmine inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:22001777 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Axin2 |
axin 2 |
multiple interactions |
ISO |
Harmine inhibits the reaction [WNT3A protein results in increased expression of AXIN2 mRNA] |
CTD |
PMID:20519739 |
|
NCBI chr10:97,212,483...97,238,824
Ensembl chr10:97,212,432...97,239,642
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions |
ISO |
Harmine promotes the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L11 protein] |
CTD |
PMID:30171258 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Ccna1 |
cyclin A1 |
increases expression |
ISO |
Harmine results in increased expression of CCNA1 mRNA; Harmine results in increased expression of CCNA1 protein |
CTD |
PMID:25751815 |
|
NCBI chr 2:144,456,689...144,503,570
Ensembl chr 2:144,458,153...144,467,912
|
|
G |
Ccne2 |
cyclin E2 |
increases expression |
ISO |
Harmine results in increased expression of CCNE2 mRNA; Harmine results in increased expression of CCNE2 protein |
CTD |
PMID:25751815 |
|
NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
|
|
G |
Cdc25a |
cell division cycle 25A |
increases expression |
ISO |
Harmine results in increased expression of CDC25A mRNA |
CTD |
PMID:25751815 |
|
NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
|
|
G |
Cdc25c |
cell division cycle 25C |
increases expression |
ISO |
Harmine results in increased expression of CDC25C mRNA |
CTD |
PMID:25751815 |
|
NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression |
ISO |
Harmine results in increased expression of CDK1 mRNA; Harmine results in increased expression of CDK1 protein |
CTD |
PMID:25751815 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases phosphorylation |
EXP |
Harmine results in decreased phosphorylation of CDKN1B protein |
CTD |
PMID:26953159 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
decreases expression |
ISO |
Harmine results in decreased expression of CDKN1C mRNA; Harmine results in decreased expression of CDKN1C protein |
CTD |
PMID:25751815 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression |
ISO |
Harmine results in decreased expression of CDKN2A mRNA; Harmine results in decreased expression of CDKN2A protein |
CTD |
PMID:25751815 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
decreases expression |
ISO |
Harmine results in decreased expression of CDKN2B mRNA |
CTD |
PMID:25751815 |
|
NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
multiple interactions increases phosphorylation |
ISO |
AZD 6244 inhibits the reaction [Harmine results in increased phosphorylation of CHD4 protein]; Harmine inhibits the reaction [CHD4 protein affects the expression of UCP1 mRNA]; Harmine inhibits the reaction [CHD4 protein binds to UCP1 promoter] |
CTD |
PMID:27805061 |
|
NCBI chr 4:157,612,531...157,645,660
Ensembl chr 4:157,612,536...157,645,659
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
multiple interactions increases expression |
ISO |
Harmine affects the reaction [Dietary Fats affects the expression of CIDEA mRNA] Harmine results in increased expression of CIDEA protein |
CTD |
PMID:27805061 |
|
NCBI chr18:63,082,861...63,108,450
Ensembl chr18:63,098,144...63,108,051
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity decreases stability |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Harmine results in decreased stability of CYP1A1 protein]; Harmine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Harmine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Harmine results in decreased activity of CYP1A1 protein |
CTD |
PMID:22001777 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
increases expression |
ISO |
Harmine results in increased expression of DIO2 protein |
CTD |
PMID:27805061 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dyrk1a |
dual specificity tyrosine phosphorylation regulated kinase 1A |
multiple interactions affects binding decreases activity |
ISO |
Harmine inhibits the reaction [DYRK1A protein results in increased phosphorylation of MAPT protein] Harmine binds to DYRK1A protein Harmine results in decreased activity of DYRK1A protein |
CTD |
PMID:21573099 PMID:25751815 |
|
NCBI chr11:34,858,339...34,958,733
Ensembl chr11:34,865,532...34,956,536
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression |
ISO |
Harmine results in increased expression of E2F1 mRNA; Harmine results in increased expression of E2F1 protein |
CTD |
PMID:25751815 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
E2f2 |
E2F transcription factor 2 |
increases expression |
ISO |
Harmine results in increased expression of E2F2 mRNA; Harmine results in increased expression of E2F2 protein |
CTD |
PMID:25751815 |
|
NCBI chr 5:154,516,611...154,540,228
Ensembl chr 5:154,522,119...154,540,265
|
|
G |
E2f7 |
E2F transcription factor 7 |
increases expression |
ISO |
Harmine results in increased expression of E2F7 mRNA |
CTD |
PMID:25751815 |
|
NCBI chr 7:53,275,659...53,318,261
Ensembl chr 7:53,275,676...53,316,481
|
|
G |
E2f8 |
E2F transcription factor 8 |
increases expression |
ISO |
Harmine results in increased expression of E2F8 mRNA |
CTD |
PMID:25751815 |
|
NCBI chr 1:104,185,436...104,203,683
Ensembl chr 1:104,187,100...104,202,591
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
[phenylamil co-treated with Harmine] results in increased expression of FABP4 mRNA |
CTD |
PMID:20519739 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Foxm1 |
forkhead box M1 |
increases expression |
ISO |
Harmine results in increased expression of FOXM1 mRNA; Harmine results in increased expression of FOXM1 protein |
CTD |
PMID:25751815 |
|
NCBI chr 4:161,685,236...161,697,633
Ensembl chr 4:161,685,258...161,696,305
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
multiple interactions |
ISO |
Harmine inhibits the reaction [WNT3A protein results in decreased expression of ID2 mRNA] |
CTD |
PMID:20519739 |
|
NCBI chr 6:44,360,077...44,361,908
Ensembl chr 6:44,348,501...44,363,915
|
|
G |
Ins2 |
insulin 2 |
increases expression |
ISO |
Harmine results in increased expression of INS mRNA |
CTD |
PMID:25751815 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
Harmine affects the reaction [LEPR protein affects the susceptibility to INS1 protein] |
CTD |
PMID:27805061 |
|
NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
|
|
G |
Mafa |
MAF bZIP transcription factor A |
increases expression |
ISO |
Harmine results in increased expression of MAFA mRNA; Harmine results in increased expression of MAFA protein |
CTD |
PMID:25751815 |
|
NCBI chr 7:116,779,368...116,781,815
Ensembl chr 7:116,780,681...116,781,766
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
EXP ISO |
Harmine results in decreased activity of MAOA protein |
CTD |
PMID:24373881 PMID:28302559 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Harmine results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:27805061 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Harmine results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:27805061 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
Harmine inhibits the reaction [DYRK1A protein results in increased phosphorylation of MAPT protein] |
CTD |
PMID:21573099 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
ISO |
Harmine results in increased expression of MYC protein |
CTD |
PMID:25751815 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
affects localization |
ISO |
Harmine affects the localization of NFATC1 protein |
CTD |
PMID:25751815 |
|
NCBI chr18:77,203,517...77,322,690
Ensembl chr18:77,203,525...77,322,690
|
|
G |
Nfatc2 |
nuclear factor of activated T-cells 2 |
affects localization |
ISO |
Harmine affects the localization of NFATC2 protein |
CTD |
PMID:25751815 |
|
NCBI chr 3:165,241,750...165,374,644
Ensembl chr 3:165,245,238...165,360,292
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
affects localization |
ISO |
Harmine affects the localization of NFATC3 protein |
CTD |
PMID:25751815 |
|
NCBI chr19:38,039,542...38,114,003
Ensembl chr19:38,039,564...38,114,003
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
affects localization |
ISO |
Harmine affects the localization of NFATC4 protein |
CTD |
PMID:25751815 |
|
NCBI chr15:34,493,163...34,502,238
Ensembl chr15:34,493,138...34,504,326
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Harmine promotes the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein] |
CTD |
PMID:30171258 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pdx1 |
pancreatic and duodenal homeobox 1 |
increases expression |
ISO |
Harmine results in increased expression of PDX1 mRNA; Harmine results in increased expression of PDX1 protein |
CTD |
PMID:25751815 |
|
NCBI chr12:9,496,044...9,501,211
Ensembl chr12:9,496,044...9,501,213
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
[phenylamil co-treated with Harmine] results in increased expression of PPARG mRNA Harmine results in increased expression of PPARG protein |
CTD |
PMID:20519739 PMID:27805061 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
Harmine results in increased expression of PPARGC1A protein Harmine affects the reaction [Dietary Fats affects the expression of PPARGC1A mRNA] |
CTD |
PMID:27805061 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Prdm16 |
PR/SET domain 16 |
increases expression multiple interactions |
ISO |
Harmine results in increased expression of PRDM16 protein Harmine affects the reaction [Dietary Fats affects the expression of PRDM16 mRNA] |
CTD |
PMID:27805061 |
|
NCBI chr 5:171,662,277...171,711,561
Ensembl chr 5:171,662,277...171,710,316
|
|
G |
Ucp1 |
uncoupling protein 1 |
increases expression multiple interactions |
ISO |
Harmine results in increased expression of UCP1 mRNA; Harmine results in increased expression of UCP1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Harmine results in increased expression of UCP1 mRNA]; AZD 6244 inhibits the reaction [Harmine results in increased expression of UCP1 mRNA]; Harmine affects the reaction [Dietary Fats affects the expression of UCP1 mRNA]; Harmine inhibits the reaction [CHD4 protein affects the expression of UCP1 mRNA]; Harmine inhibits the reaction [CHD4 protein binds to UCP1 promoter]; N4-(9-ethyl-9H-carbazol-3-yl)-N2-(3-morpholin-4-ylpropyl)-pyrimidine-2,4-diamine inhibits the reaction [Harmine results in increased expression of UCP1 mRNA] |
CTD |
PMID:27805061 |
|
NCBI chr19:24,456,976...24,464,808
Ensembl chr19:24,456,976...24,464,807
|
|
G |
Wnt3a |
Wnt family member 3A |
multiple interactions |
ISO |
Harmine inhibits the reaction [WNT3A protein results in decreased expression of ID2 mRNA]; Harmine inhibits the reaction [WNT3A protein results in increased expression of AXIN2 mRNA] |
CTD |
PMID:20519739 |
|
NCBI chr10:45,598,898...45,643,151
Ensembl chr10:45,598,912...45,638,035
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases localization increases expression multiple interactions affects binding |
ISO EXP |
rutecarpine results in increased localization of AHR protein rutecarpine results in increased expression of AHR mRNA 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [rutecarpine results in increased localization of AHR protein]; AHR affects the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; AHR affects the reaction [rutecarpine results in increased expression of CYP1A1 mRNA]; rutecarpine promotes the reaction [AHR protein binds to CYP1A1 promoter]; W 7 inhibits the reaction [rutecarpine results in increased localization of AHR protein] 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [rutecarpine binds to AHR protein]; rutecarpine inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; W 7 inhibits the reaction [rutecarpine binds to AHR protein] |
CTD |
PMID:19853001 PMID:20449727 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Ahrr |
aryl-hydrocarbon receptor repressor |
increases expression |
ISO |
rutecarpine results in increased expression of AHRR mRNA |
CTD |
PMID:20449727 |
|
NCBI chr 1:31,603,297...31,698,329
Ensembl chr 1:31,603,297...31,698,329
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor type 1A |
decreases expression |
ISO |
rutecarpine results in decreased expression of BMPR1A mRNA |
CTD |
PMID:25633564 |
|
NCBI chr16:10,758,278...10,852,170
Ensembl chr16:10,758,527...10,802,512
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
decreases expression |
ISO |
rutecarpine results in decreased expression of BMPR1B mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 2:247,392,195...247,662,026
Ensembl chr 2:247,403,920...247,446,882
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
decreases expression |
ISO |
rutecarpine results in decreased expression of BMPR2 mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 9:66,568,074...66,683,019
Ensembl chr 9:66,568,074...66,676,494
|
|
G |
Camk1 |
calcium/calmodulin-dependent protein kinase I |
increases phosphorylation |
ISO |
rutecarpine results in increased phosphorylation of CAMK1 protein |
CTD |
PMID:19853001 |
|
NCBI chr 4:145,289,300...145,300,146
Ensembl chr 4:145,288,996...145,300,177
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; KN 93 inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]] |
CTD |
PMID:28025122 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions affects binding increases expression |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [rutecarpine results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [rutecarpine results in increased expression of CYP1A1 mRNA]; AHR affects the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; AHR affects the reaction [rutecarpine results in increased expression of CYP1A1 mRNA]; capsazepine inhibits the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; capsazepine inhibits the reaction [rutecarpine results in increased expression of CYP1A1 mRNA]; rutecarpine promotes the reaction [AHR protein binds to CYP1A1 promoter]; rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein; W 7 inhibits the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; W 7 inhibits the reaction [rutecarpine results in increased expression of CYP1A1 mRNA] rutecarpine binds to CYP1A1 promoter 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [rutecarpine binds to CYP1A1 promoter]; W 7 inhibits the reaction [rutecarpine binds to CYP1A1 promoter] |
CTD |
PMID:19853001 PMID:20449727 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases activity |
EXP ISO |
rutecarpine promotes the reaction [CYP1A2 protein affects the metabolism of Theophylline] rutecarpine results in increased activity of CYP1A2 protein rutecarpine analog binds to and results in decreased activity of CYP1A2 protein; rutecarpine binds to and results in decreased activity of CYP1A2 protein |
CTD |
PMID:12852960 PMID:15720787 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
rutecarpine analog binds to and results in decreased activity of CYP1B1 protein |
CTD |
PMID:12852960 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases expression |
ISO |
rutecarpine results in decreased expression of FURIN mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:142,185,092...142,198,167
Ensembl chr 1:142,185,094...142,197,182
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GPT protein] |
CTD |
PMID:28025122 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
multiple interactions decreases expression |
ISO |
rutecarpine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] rutecarpine results in decreased expression of HAMP mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hjv |
hemojuvelin BMP co-receptor |
decreases expression |
ISO |
rutecarpine results in decreased expression of HJV mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 2:198,655,437...198,659,318
Ensembl chr 2:198,655,437...198,659,317
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of HMOX1 protein] |
CTD |
PMID:28025122 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
rutecarpine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
rutecarpine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:17109845 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of NQO1 protein] |
CTD |
PMID:28025122 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|